BOBBI BRUMLEY: Open Payments
NPI 1255015814 · HOT SPRINGS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,377 in 160 payments from 18 companies in 2025. Trend: 2023 $198 · 2024 $1,442 · 2025 $2,377
Food & beverage: $2,377
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 42 | $379 |
| Otsuka America Pharmaceutical, Inc. | 16 | $363 |
| AstraZeneca Pharmaceuticals LP | 18 | $312 |
| Novo Nordisk Inc | 14 | $197 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $189 |
| Lilly USA, LLC | 11 | $159 |
| Viatris Specialty LLC | 12 | $153 |
| Aimmune Therapeutics, Inc. | 6 | $116 |
| Sumitomo Pharma America, Inc. | 7 | $109 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $104 |
Products named: REXULTI, UBRELVY, CAPLYTA, YUPELRI, AIRSUPRA, ZENPEP, FARXIGA, GEMTESA.
Industry payments across AR — which companies pay providers there.
